2Morrison S L, Johnson M J, Herzenberg L A, et al. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA, 1984, 81:6851 -6855.
3沈倍奋,陈志南,刘民培.重组抗体.北京:科学出版社,2005.217-234.
4Booy E P, Johar D, Maddika S,et al. Monoclonal and bispecific antibodies as novel therapeutics.
5Hwang W Y, Foote J. Immunogenicity of engineered antibodies. Methods, 2005, 36 ( 1 ) :3 - 10.
6Kashmiri S V, De Pascalis R, Gonzales N R, et al. SDR grafting a new approach to antibody humanization. Methods, 2005, 36 (1) :25 -34.
7Clark M. Antibody humanization : a case of the ‘ Emperor' s new clothes' ? Immunol Today, 2000, 21 (8) :397 - 402.
8Leonard J P, Coleman M, Ketas J C, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin' s lymphoma. Clin Cancer Res, 2004, 10 (16) : 5327 N5334.
9Haymes L M, Tonkin J, Anderson L J, et al. Neutralizing anti-F glycoprotein and anti-substance Pantibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection. J Virol, 2002, 76 (14) : 6873 -6881.
10Lambert M P, Barlow A K, Chromy B A, et al. Diffusible, nonfibrillar ligands derived from Abetal-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A, 1998, 95 ( 11 ) :6448 - 6453.
1HE JinSheng1, ZHANG Ying1 & HONG Tao1,2 1College of Life Sciences and Bioengineering, School of Science, Beijing Jiaotong University, Beijing 100044, China,2Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 100052, China.Progress in the development of therapeutic antibodies targeting prion proteins and β-amyloid peptides[J].Science China(Life Sciences),2010,53(8):959-963. 被引量：1
